Could Sanofi – Adr (NASDAQ:SNY) Go Down After Its Newest Short Interest Report?

Sanofi (NASDAQ:SNY) Logo

The stock of Sanofi – Adr (NASDAQ:SNY) registered a decrease of 12.59% in short interest. SNY’s total short interest was 1.97 million shares in August as published by FINRA. Its down 12.59% from 2.25 million shares, reported previously. With 1.42M shares average volume, it will take short sellers 1 days to cover their SNY’s short positions. The short interest to Sanofi – Adr’s float is 0.08%.

The stock decreased 0.24% or $0.1 during the last trading session, reaching $41.65. About 995,740 shares traded. Sanofi (NASDAQ:SNY) has declined 2.87% since August 16, 2018 and is downtrending. It has underperformed by 2.87% the S&P500.

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company has market cap of $105.29 billion. The firm operates in two divisions, Pharmaceuticals and Vaccines. It has a 21.47 P/E ratio. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

More notable recent Sanofi (NASDAQ:SNY) news were published by: which released: “Buy Merck & Co (MRK) Stock Ahead of Q2 Earnings Report? – Nasdaq” on July 25, 2019, also with their article: “Company News For Jul 30, 2019 – Nasdaq” published on July 30, 2019, published: “Sanofi appoints Novartis exec as new CEO – Seeking Alpha” on June 07, 2019. More interesting news about Sanofi (NASDAQ:SNY) were released by: and their article: “Sanofi Breaks Below 200-Day Moving Average – Notable for SNY – Nasdaq” published on July 08, 2019 as well as‘s news article titled: “Sanofi: Performance Review And Way Forward – Seeking Alpha” with publication date: February 28, 2019.

Sanofi (NASDAQ:SNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.